Dr.-Nicoline Breet and colleagues at The San Antonius Center for Platelet Function Research in the Netherlands studied 1, 069 patients on clopidogrel undergoing elective PCI with stent implant. They noted that up to 36% of patients do not achieve an optimal degree of platelet inhibition in response to taking clopidogrel. A head-to-head comparison of platelet function assays was undertaken, including laboratory-based light transmittance PRP platelet aggregometry, Helena Plateletworks and five other assays to see if the clinical outcome of these patients could be predicted by their degree of platelet inhibition.- The primary endpoints were the occurrence of an adverse cardiac event, including death, MI, stent thrombosis within one year, as well as incidence of major or minor bleeding.
Of the seven assays studied, only traditional aggregometry, Plateletworks and one other assay were able to identify patients at higher risk for an adverse cardiac event. None were predictive of TIMI major or minor bleeding.- The study results were presented at the American Heart Association Scientific Session in November of 2009 and were reported on the online cardiology site, the heart.org.- http://www.theheart.org/article/1021875.do